Loading
The trial that made camrelizumab a first-line lung cancer option in China, one of several domestic PD-1 antibodies to reproduce the KEYNOTE-189 result.
412 patients, open label. Median progression-free survival 11.3 versus 8.3 months (hazard ratio 0.60); overall survival favoured camrelizumab in later follow-up. NMPA approval June 2020. Its companion CameL-sq did the same in squamous disease. Camrelizumab is notable for reactive cutaneous capillary endothelial proliferation, a side effect largely unique to it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
A second publication from the CameL trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT03134872 with the most citations, so it is the natural first reading for anyone following the CameL trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals and the tag china.
Shares Caicun Zhou, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag china.
Shares Pemetrexed, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag china.
Shares Jiangsu Hengrui Pharmaceuticals, Carboplatin, Immune checkpoint inhibitors and the tag china.
Shares Pemetrexed, Carboplatin, Non-small-cell lung cancer and the tag china.
Shares Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag china.
Shares Non-small-cell lung cancer and the tag china.
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals and the tag china.